Thermo Fisher Scientific Payments to Acquire Investments decreased by 94.7% to $14.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 94.7%, from $264.00M to $14.00M.
Increases suggest a strategy of diversifying capital or building strategic partnerships, while decreases may indicate a focus on core operations.
This represents cash outflows for the purchase of financial assets, such as equity stakes in other companies, debt secur...
Commonly found in the investing section of the cash flow statement as 'Payments to acquire investments' or 'Purchases of securities'.
other_payments_to_acquire_investments| Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|
| Value | $2.00M | $186.00M | $12.00M | $1.76B | $20.00M | $287.00M | $264.00M | $14.00M |
| QoQ Change | — | >999% | -93.5% | >999% | -98.9% | >999% | -8.0% | -94.7% |
| YoY Change | — | — | — | >999% | -89.2% | >999% | -85.0% | -94.7% |